Efficacy of methylnaltrexone for the treatment of opiod-induced constipation: a meta-analysis and systematic review

References

• Chapman CR, Lipschitz DL, Angst MS, et al. Opioid pharmacotherapy for chronic non-cancer pain in the United States: a research guideline for developing an evidence-base. J Pain. 2010;11(9):807–829. doi:10.1016/j.jpain.2010.02.019.
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Vallejo R, Manchikanti KN, et al. Christo PJ. Effectiveness of long-term opioid therapy for chronic non-cancer pain. Pain Physician. 2011;14(2):E133–156. [cited 2014 Oct 13]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21412378.
   PubMed Web of Science ®Google Scholar
• Opioid Painkiller Prescribing. Vital Signs, Centers Dis Control Prev; 2014 [cited 2014 Oct 9]. Available from: http://www.cdc.gov/vitalsigns/opioid-prescribing/
   Google Scholar
• Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol. 2011;106(5):835–842. quiz 843. doi:10.1038/ajg.2011.30.
   PubMed Web of Science ®Google Scholar
• Thapa D, Rastogi V, Ahuja V. Cancer pain management-current status. J Anaesthesiol Clin Pharmacol. 2011;27(2):162–168. doi:10.4103/0970-9185.81820.
   PubMedGoogle Scholar
• Edgerton L, Loven B. Clinical inquiries. What are the adverse effects of prolonged opioid use in patients with chronic pain? J Fam Pract. 2011;60(5):288–289. [cited 2014 Oct 13]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21544277
   PubMed Web of Science ®Google Scholar
• Jamshed N, Lee Z-E, Olden KW. Diagnostic approach to chronic constipation in adults. Am Fam Physician. 2011;84(3):299–306. [cited 2014 Oct 13]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21842777
   PubMed Web of Science ®Google Scholar
• Twycross R, Sykes N, Mihalyo M, et al. Stimulant laxatives and opioid-induced constipation. J Pain Symptom Manage. 2012;43(2):306–313. doi:10.1016/j.jpainsymman.2011.12.002.
   PubMed Web of Science ®Google Scholar
• Kalso E, Edwards JE, Moore AR, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372–380. doi:10.1016/j.pain.2004.09.019.
   PubMed Web of Science ®Google Scholar
• Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010;1:CD006605. doi:10.1002/14651858.CD006605.pub2.
   PubMed Web of Science ®Google Scholar
• Bader S, Jaroslawski K, Blum HE, et al. Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide. Clin Med Insights Oncol. 2011;5:201–211. doi:10.4137/CMO.S4867.
   PubMedGoogle Scholar
• Michna E, Blonsky ER, Schulman S, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain. 2011;12(5):554–562. doi:10.1016/j.jpain.2010.11.008.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Thomas J, Moehl Boatwright ML, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008;35(5):458–468. doi:10.1016/j.jpainsymman.2007.12.005.
   PubMed Web of Science ®Google Scholar
• Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009;7(1):39–46. [cited 2014 Oct 13]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19278178.
   PubMedGoogle Scholar
• Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332–2343. doi:10.1056/NEJMoa0707377.
   PubMed Web of Science ®Google Scholar
• Ford AC, Brenner DM, Schoenfeld PS. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. Am J Gastroenterol. 2013;108(10):1566–1574. quiz 1575. doi:10.1038/ajg.2013.169.
   PubMed Web of Science ®Google Scholar
• Moher D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264. doi:10.7326/0003-4819-151-4-200908180-00135.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions, version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Available from: www.cochrane-handbook.org.
   Google Scholar
• Anissian L, Schwartz HW, Vincent K, et al. Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery. J Hosp Med. 2012;7(2):67–72. doi:10.1002/jhm.943.
   PubMed Web of Science ®Google Scholar
• Karver SB, Slatkin NE, Thomas J, et al. Methylnaltrexone treatment of opioid-induced constipation in cancer patients. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 9081. [cited 2014 March 27]. Available from: www.asco.org/ASCO/Abstracts+%26+Virtual+meeting/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=35781
   Google Scholar
• Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and european patient survey (PROBE 1). Pain Med. 2009;10(1):35–42. doi:10.1111/j.1526-4637.2008.00495.x.
   PubMed Web of Science ®Google Scholar
• Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the national health and wellness survey. J Opioid Manag. 5(3):137–144. [Accessed October 13, 2014]. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19662923.
   PubMedGoogle Scholar
• Crownover B, Zimmerman E. Methylnaltrexone (Relistor) for opioid-induced constipation. Am Fam Physician. 2010;82(6): 678–681.
   Web of Science ®Google Scholar
• Mackey AC, Green L, Greene P, et al. Methylnaltrexone and gastrointestinal perforation. J Pain Symptom Manage. 2010 Jul;40(1):e1–3. doi:10.1016/j.jpainsymman.2010.01.011.
   PubMedGoogle Scholar
• Webster L, Michna E, Khan A, et al. The long-term efficacy of subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic nonmalignant pain. J Pain. 2011;12(4):70.
   Google Scholar
• Candrilli SD, Davis KL, Iyer S. Impact of constipation on opioid use patterns, health care resource utilization, and costs in cancer patients on opioid therapy. J Pain Palliat Care Pharmacother. 2009;23(3):231–241. doi:10.1080/15360280903098440.
   PubMedGoogle Scholar
• Leung L, Riutta T, Kotecha J, et al. Chronic constipation: an evidence-based review. J Am Board Fam Med. 2011;24(4):436–451. doi:10.3122/jabfm.2011.04.100272.
   PubMed Web of Science ®Google Scholar
• Deibert P, Xander C, Blum HE, et al. Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation. Core Evidence. 2009;4:247–258.
   Google Scholar
• Corporation G and A. GSK and Adolor announce preliminary results from phase 3 safety study of alvimopan (Entereg/Entrareg). [cited 2008 June 26] Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=120919&p=irolnewsArticle&t=Regular&id=982960&
   Google Scholar
• Chey W, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370:2387–2396. doi:10.1056/NEJMoa1310246.
   PubMed Web of Science ®Google Scholar
• Ahmedzai SH, Leppert W, Janecki M, et al. Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. Support Care Cancer. 2015 Mar;23(3):823–830. doi:10.1007/s00520-014-2435-5.
   PubMed Web of Science ®Google Scholar
• Blagden M, Hafer J, Duerr H, et al. Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trials. Neurogastroenterol Motil. 2014 Dec;26(12):1792–1801. doi:10.1111/nmo.12463.
   PubMed Web of Science ®Google Scholar
• Leppert W. Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction. Drug Des Devel Ther. 2015;9:2215–2231. doi:10.2147/DDDT.S32684.
   PubMed Web of Science ®Google Scholar
• Food and drug administration center for drug evaluation and research: briefing document-anesthetic and analgesic drug products advisory committee meeting. June 11-12, 2014, 8–9.
   Google Scholar